Beruflich Dokumente
Kultur Dokumente
2
Why vaccines? Equity and feasibility
qVaccine delivery
systems designed to
reach every individual
regardless of:
• Socioeconomic status
• Geography
• Age
• Sex
qCurative care limited by
requirement for fixed
structures
3
Why vaccines? Affordability
4
CVD Approach: From Discovery to Impact
Political Will
Vaccines: A continuum from Discovery to Impact
5
CVD research areas
Enteric Diseases CVD has developed and tested vaccines against Shigella
and Enterotoxigenic E. coli, cholera, NTS and others. Leading Typhoid
Vaccine Acceleration Consortium (TyVAC).
Malaria – development and testing of malaria drugs and vaccines and other
interventions; antimalarial drug resistance; malaria transmission.
Malaria Research
Program
CVD-Mali (2001)
9
CVD-Mali Impact
Generated evidence to support introduction of
5 new vaccines 2005-2014
ü Hib pentavalent
ü Meningitis A
ü PCV13
ü Rotavirus
ü HPV 2011 (pilot)
10
Example: Timeline of NTS vaccine program
• Typhoid continues to be a
substantial public health threat.
• Increasing recognition of the
burden in young children.
• Outbreaks of typhoid continue.
• Antimicrobial resistance to the
most effective treatments is on the Percent of population with improved drinking
water sources, 2015.
rise.
• Improvements in water, sanitation,
and hygiene continue to lag in UNICEF and WHO. 2015
many parts of the world.
COLLABORATING ORGANIZATIONS
A framework for accelerating TCV introduction
Policy milestones impacting TCV introduction
Number vaccinated
• TyVAC Malawi: 28,142
• TyVAC Burkina Faso:
250
Number vaccinated
• TyVAC Bangladesh 61,756
• TyVAC Nepal: 20,015
• Navi Mumbai India: ~ 113,000
• Pakistan (outbreak response): Goal of 250,000
Potential barriers to TCV
introduction
• Insufficient burden data to
assess country need.
• Difficult to apply risk-based
strategy in absence of incidence
data or population risk factors.
• What happens as countries
graduate from Gavi?
• Prioritizing long queue of
vaccines for introduction.
• Vaccine introduction/campaign
fatigue.
Country introduction: A collaborative
effort
• Review and collate burden data for TCV
introduction.
• Participate in national and local
discussion on typhoid data to build
consensus on burden.
• Decision-making and plan of action.
• Gavi application assistance.
• Country-specific materials to support
introduction.
• Post-introduction support.
Training the next generation of vaccinologists
and global health scientists